抗CD20モノクローナル抗体 (mAbs)の世界市場の評価：製品タイプ別、適応症別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

世界の抗CD20モノクローナル抗体 (mAbs) の市場規模は、予測期間中にCAGR 9.84％で成長し、2023年の101億2,000万米ドルから、2031年には214億4,000万米ドルに成長すると予測されています。

同市場は近年著しい成長を遂げており、今後も力強い拡大ペースを維持すると予想されます。世界の抗CD20モノクローナル抗体 (mAbs) 市場の成長は、自己免疫疾患の有病率の上昇、技術の進歩、医療研究への投資の増加、政府の取り組み、償還政策などさまざまな要因によって牽引されています。

政府のイニシアチブ、有利な償還政策、自己免疫疾患の適切な管理における抗CD20 mAbsの潜在的な利点に関する意識の高まりから、これらの抗体の使用が推進されています。また、企業各社は質の高い医療を提供するため、イノベーション、新製品、より効率的で効果的な抗CD20 mAbs開発に向けたR&Dに投資しています。さらに、共同研究、M&A、規制政策の拡大も同市場の成長をさらに促進しています。

自己免疫疾患の世界の有病率の増加は、世界の抗CD20 mAbs市場の主要な促進要因です。関節リウマチ、全身性エリテマトーデス (ループス) 、炎症性腸疾患 (IBD) 、多発性硬化症がもっとも一般的な自己免疫疾患の一部です。Global Autoimmune Instituteは、2022年には世界人口の4％が少なくとも1つの自己免疫疾患に罹患していると述べています。リツキシマブなどの抗CD20 mAbsは、自己免疫疾患の治療において大きな可能性を示しており、そのため医療従事者や患者の間で需要が増加しています。

用途別では、免疫分野が最大のシェアを占めています。これらの抗体は、関節リウマチ、多発性硬化症、全身性エリテマトーデスなど、さまざまな免疫疾患の治療に成功しています。また、エンドユーザー別では、病院が大きなシェアを占めています。自己免疫疾患の有病率が上昇し、高度な治療が利用できるようになったことが、病院におけるmAb治療の需要を促進しています。地域別では、北米がもっとも高いシェアを占めています。同地域の強固な医療インフラ、国民により良い医療を提供するための高額な医療予算と投資、革新的で効率的な医薬品を開発するための研究開発などの要因が北米市場の著しい成長につながっています。

当レポートでは、世界の抗CD20モノクローナル抗体 (mAbs) の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の抗CD20モノクローナル抗体 (mAbs) 市場の展望

• 市場規模・予測
• 製品タイプ別
  • 第1世代CD20モノクローナル抗体
  • 第2世代CD20モノクローナル抗体
  • 第3世代CD20モノクローナル抗体
• 適応症別
  • 腫瘍
  • 神経内科
  • 免疫
  • その他
• エンドユーザー別
  • 病院
  • 専門クリニック
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 企業別市場シェア

第5章 世界の抗CD20モノクローナル抗体 (mAbs) 市場の展望：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 市場マッピング

• 製品タイプ別
• 適応症別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

• 臨床試験
• 特許の情勢
• 規制当局の承認
• イノベーション/最新技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)
• 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Genmab A/S
• Biogen Inc.
• Novartis AG
• AbbVie Inc.
• TG Therapeutics, Inc.
• Gilead Sciences, Inc.
• AstraZeneca Plc.
• AbCellera Biologics Inc.
• Bio-Rad Laboratories, Inc.

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 2. Global Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 3. Global Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 4. Global Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 5. Global Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 6. Global Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Region, 2017-2031F
• Figure 7. North America Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 8. North America Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 9. North America Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 10. North America Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 11. North America Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 12. North America Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Country, 2017-2031F
• Figure 13. United States Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 14. United States Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 15. United States Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 16. United States Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 17. United States Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 18. Canada Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 19. Canada Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 20. Canada Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 21. Canada Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 22. Canada Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 23. Mexico Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 24. Mexico Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 25. Mexico Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 26. Mexico Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 27. Mexico Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 28. Europe Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 29. Europe Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 30. Europe Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 31. Europe Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 32. Europe Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 33. Europe Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Country, 2017-2031F
• Figure 34. Germany Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 35. Germany Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 36. Germany Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 37. Germany Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 38. Germany Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 39. France Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 40. France Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 41. France Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 42. France Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 43. France Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 44. Italy Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 45. Italy Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 46. Italy Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 47. Italy Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 48. Italy Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 49. United Kingdom Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 50. United Kingdom Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 51. United Kingdom Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 52. United Kingdom Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 53. United Kingdom Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 54. Russia Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 55. Russia Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 56. Russia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 57. Russia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 58. Russia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 59. Netherlands Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 60. Netherlands Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 61. Netherlands Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 62. Netherlands Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 63. Netherlands Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 64. Spain Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 65. Spain Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 66. Spain Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 67. Spain Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 68. Spain Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 69. Turkey Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 70. Turkey Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 71. Turkey Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 72. Turkey Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 73. Turkey Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 74. Poland Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 75. Poland Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 76. Poland Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 77. Poland Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 78. Poland Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 79. South America Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 80. South America Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 81. South America Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 82. South America Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 83. South America Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 84. South America Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Country, 2017-2031F
• Figure 85. Brazil Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 86. Brazil Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 87. Brazil Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 88. Brazil Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 89. Brazil Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 90. Argentina Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 91. Argentina Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 92. Argentina Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 93. Argentina Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 94. Argentina Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 95. Asia-Pacific Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 96. Asia-Pacific Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 97. Asia-Pacific Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 98. Asia-Pacific Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 99. Asia-Pacific Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 100. Asia-Pacific Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Country, 2017-2031F
• Figure 101. India Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 102. India Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 103. India Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 104. India Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 105. India Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 106. China Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 107. China Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 108. China Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 109. China Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 110. China Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 111. Japan Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 112. Japan Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 113. Japan Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 114. Japan Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 115. Japan Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 116. Australia Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 117. Australia Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 118. Australia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 119. Australia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 120. Australia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 121. Vietnam Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 122. Vietnam Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 123. Vietnam Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 124. Vietnam Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 125. Vietnam Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 126. South Korea Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 127. South Korea Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 128. South Korea Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 129. South Korea Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 130. South Korea Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 131. Indonesia Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 132. Indonesia Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 133. Indonesia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 134. Indonesia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 135. Indonesia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 136. Philippines Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 137. Philippines Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 138. Philippines Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 139. Philippines Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 140. Philippines Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 141. Middle East & Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 142. Middle East & Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 143. Middle East & Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 144. Middle East & Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 145. Middle East & Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 146. Middle East & Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Country, 2017-2031F
• Figure 147. Saudi Arabia Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 148. Saudi Arabia Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 149. Saudi Arabia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 150. Saudi Arabia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 151. Saudi Arabia Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 152. UAE Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 153. UAE Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 154. UAE Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 155. UAE Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 156. UAE Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 157. South Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Value, in USD Billion, 2017-2031F
• Figure 158. South Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market, By Volume, in Million Units, 2017-2031F
• Figure 159. South Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Product Type, 2017-2031F
• Figure 160. South Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By Indication, 2017-2031F
• Figure 161. South Africa Anti-CD20 Monoclonal Antibodies (mAbs) Market Share (%), By End-user, 2017-2031F
• Figure 162. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global anti-CD20 monoclonal antibodies (mAbs) market is projected to witness a CAGR of 9.84% during the forecast period 2024-2031, growing from USD 10.12 billion in 2023 to USD 21.44 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. The growth in the global anti-CD20 monoclonal antibodies (mAbs) market is driven by various factors such as the rising prevalence of autoimmune diseases, technological advancements, increasing investments in healthcare research, government initiatives, and reimbursement policies.

Growing private and public sector investments in the market, presence of several established players and strategies such as mergers and acquisitions, collaborations, and product launches are accelerating the global anti-CD20 monoclonal antibodies market growth. The global anti-CD20 mAbs market is further undergoing robust growth due to rise in prevalence of autoimmune diseases at global level. Anti-CD20 mAbs play a crucial role in the management of these autoimmune diseases. Anti-CD20 monoclonal antibodies are one of the most effective antibodies used in treatment of a wide range of diseases including cancer and immune related disorders. Other factors, such as improvements in healthcare facilities and technological advancements in the market, are further accelerating the growth of the global anti-CD20 mAbs market.

Government initiatives, favorable reimbursement policies, and growing awareness regarding the potential benefits of these antibodies in the proper management of auto-immune disease further encourage the use of these antibodies among the population. Due to these factors, several public and private companies invest in innovations, new products, and research and development of more efficient and effective anti-CD20 mAbs developments to provide quality medical treatment. Moreover, growing collaborations, mergers and acquisitions, and regulatory policies will further drive the growth of the global anti-CD20 monoclonal antibodies market.

In May 2023, Genmab A/S specialized in the development of differentiated antibody therapeutics to fight against cancer and other serious diseases announced that it received U.S. Food and Drug Administration (FDA) approval for EPKINLY (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Increasing Prevalence of Autoimmune Diseases

The increasing prevalence of autoimmune diseases globally is a major driving factor for the global anti-CD20 mAbs market. Rheumatoid arthritis, systemic lupus erythematosus (lupus), inflammatory bowel disease (IBD), and multiple sclerosis are some of the most common autoimmune diseases. Both developed and developing countries are affected by immunological disorders. Global Autoimmune Institute stated that in 2022, 4% of the world's population had at least one autoimmune disease. Autoimmune diseases are becoming more prevalent each year. Family history of autoimmune diseases, with at least one autoimmune disease, obesity, excessive tobacco consumption, and early exposure to certain infections are the leading risk factors for the rising prevalence of autoimmune diseases. Anti-CD20 mAbs such as Rituximab have shown tremendous potential in treating autoimmune diseases, due to which demand among the healthcare providers and patients is increasing. Growing awareness regarding the potential benefits of these antibodies in management of several diseases is driving the growth of the global anti-CD20 monoclonal antibodies market.

Technological Advancement in Anti-CD20 Monoclonal Antibodies (mAbs)

Anti-CD20 monoclonal antibodies have the potential to treat several autoimmune diseases and cancers. Due to its phenomenal success, there has been continuous development in the market, such as the development of first-generation CD20 monoclonal antibodies such as rituximab, second-generation CD20 monoclonal antibodies such as ocrelizumab, obinutuzumab, and veltuzumab and third generation CD20 monoclonal antibodies such as ocaratuzumab and PRO131921. In recent years, there has been a surge of innovative technologies aimed at overcoming the limitations of previous drugs, and we are in the process of bringing next-generation CD20 monoclonal antibodies into the market. These technological advancements increase the accuracy and efficiency of these drugs in treating diseases.

For instance, F. Hoffmann-La Roche Ltd. has numerous drugs in pipeline under clinical trials, waiting for FDA approvals, such as Gazyva/Gazyvaro (obinutuzumab), the first glycoengineered, type II, humanized anti-CD20 monoclonal antibody which is designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN).

Growing Demand for Anti-CD20 Monoclonal Antibodies in Immunology

Amongst the application category, immunology segment holds the maximum share in the global anti-CD20 monoclonal antibodies market. These antibodies have proved to be successful in treatment for various immunological disorders such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. Due to it, key market players are performing research and development and increasing investments in developing anti-CD20 monoclonal antibodies specially for managing these immunological disorders.

According to an article published in Journal of Neurology in October 2023, anti-CD20 monoclonal antibodies have huge success in treating multiple sclerosis, an immunological disorder. Anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, ocrelizumab, and rituximab are the drugs that are either under clinical development or have been approved for the treatment of multiple sclerosis. Supportive regulatory systems enable pharmaceutical companies to invest in the research and development of these antibodies to improve their product portfolio, provide quality medical treatment, and accelerate market growth.

Hospitals Hold Dominant Share in the Market

Among the end-user segment, hospitals hold a significant market share in the global anti-CD20 monoclonal antibodies (mAbs) market. The rising prevalence of autoimmune disorders and the availability of advanced treatment methodologies are driving the demand for mAb therapy in hospitals. Anti-CD20 monoclonal antibodies are becoming popular among healthcare providers, therefore driving its adoption in specialty and multi-specialty hospitals. The use of anti-CD20 monoclonal antibodies has become standard practice in managing these conditions, contributing to improved patient outcomes and disease management. The ongoing development and clinical use of anti-CD20 monoclonal antibodies reflect their significant impact on modern healthcare and their potential for further advancements in treating various medical conditions.

North America Holds Largest Share in the Market

North America holds the highest share in the global anti-CD20 monoclonal antibodies market. The robust healthcare infrastructure of the region, along with high healthcare budgets and investments in providing improved healthcare facilities to the population involving innovative drug discoveries and manufacturing, and research and development in developing innovative, efficient drugs such as anti-CD20 monoclonal antibodies has led to the tremendous growth of the market in North America.

Moreover, the growing prevalence of autoimmune diseases in the United States and Canada has been a prominent factor in the region's huge demand for anti-CD20 monoclonal antibodies. According to Global Autoimmune Institute , in 2022, 8% of the United States population had at least one autoimmune disease. An increasing number of patients at a rapid scale is increasing demand for these potential anti-CD20 monoclonal antibodies such as Rituximab, Ofatumumab, and Obinutuzumab.

Future Market Scenario (2024 - 2031F)

Global anti-CD20 monoclonal antibodies market is expected to grow in the future, due to multiple factors. Primarily, the increasing prevalence of autoimmune diseases and cancer worldwide has increased the volume of anti-CD20 monoclonal antibodies in the healthcare industry. Increase in healthcare budgets, government initiatives, reimbursement policies, research and development, and innovative product launch by public and private bodies are further accelerating the growth of global anti-CD20 monoclonal antibodies market. Moreover, collaborative ventures involving biotech and pharmaceutical companies have spurred innovation and growth in the market.

Key Players Landscape and Outlook

In the anti-CD20 monoclonal antibodies market, public and private companies are progressively establishing initiatives, strategic partnerships, and distribution agreements, which are pivotal in driving the global anti-CD20 monoclonal antibodies market's expansion. These alliances empower firms to adapt to each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level. These collaborative initiatives promote innovation, expedite product development and improved disease treatment, and contribute to the robust growth of the healthcare industry.

In December 2022, Biogen Inc. announced that it had signed an agreement with Genentech regarding glofitamab, an anti-CD20 monoclonal antibody. The strategic acquisition will enable Biogen Inc. to earn royalties on prospective net sales of glofitamab in the United States, which will not be subjected to any payment obligations under the terms of the agreement. It will help the company to improve its product portfolio for the management of several diseases and improve medical treatment. Moreover, the partnership aims to enhance in-depth knowledge, research and development activities, and launch new products in the market that will expand their global presence.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Anti-CD20 Monoclonal Antibodies (mAbs) Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Product Type
  • 4.2.1. First Generation CD20 Monoclonal Antibodies
  • 4.2.2. Second Generation CD20 Monoclonal Antibodies
  • 4.2.3. Third Generation CD20 Monoclonal Antibodies
• 4.3. By Indication
  • 4.3.1. Oncology
  • 4.3.2. Neurology
  • 4.3.3. Immunology
  • 4.3.4. Others
• 4.4. By End-user
  • 4.4.1. Hospitals
  • 4.4.2. Specialty Clinics
  • 4.4.3. Others
• 4.5. By Region
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia-Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East and Africa
• 4.6. By Company Market Share (%), 2023

5. Global Anti-CD20 Monoclonal Antibodies (mAbs) Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Product Type
    • 5.1.2.1. First Generation CD20 Monoclonal Antibodies
    • 5.1.2.2. Second Generation CD20 Monoclonal Antibodies
    • 5.1.2.3. Third Generation CD20 Monoclonal Antibodies
  • 5.1.3. By Indication
    • 5.1.3.1. Oncology
    • 5.1.3.2. Neuroscience
    • 5.1.3.3. Immunology
    • 5.1.3.4. Others
  • 5.1.4. By End-user
    • 5.1.4.1. Hospitals
    • 5.1.4.2. Specialty Clinics
    • 5.1.4.3. Others
  • 5.1.5. United States*
    • 5.1.5.1. Market Size & Forecast
    • 5.1.5.1.1. By Value
    • 5.1.5.1.2. By Volume
    • 5.1.5.2. By Product Type
    • 5.1.5.2.1. First Generation CD20 Monoclonal Antibodies
    • 5.1.5.2.2. Second Generation CD20 Monoclonal Antibodies
    • 5.1.5.2.3. Third Generation CD20 Monoclonal Antibodies
    • 5.1.5.3. By Indication
    • 5.1.5.3.1. Oncology
    • 5.1.5.3.2. Neuroscience
    • 5.1.5.3.3. Immunology
    • 5.1.5.3.4. Others
    • 5.1.5.4. By End-user
    • 5.1.5.4.1. Hospitals
    • 5.1.5.4.2. Specialty Clinics
    • 5.1.5.4.3. Others
  • 5.1.6. Canada
  • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Product Type
• 6.2. By Indication
• 6.3. By End-user
• 6.4. By Region

7. Macro Environment and Industry Structure

• 7.1. Demand Supply Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Thermo Fisher Scientific Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. F. Hoffmann-La Roche Ltd.
• 13.3. Genmab A/S
• 13.4. Biogen Inc.
• 13.5. Novartis AG
• 13.6. AbbVie Inc.
• 13.7. TG Therapeutics, Inc.
• 13.8. Gilead Sciences, Inc.
• 13.9. AstraZeneca Plc.
• 13.10. AbCellera Biologics Inc.
• 13.11. Bio-Rad Laboratories, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer